PresentationDavid EndicottCEO & Director All right. Thanks. Let me start with just a little bit of introduction. If you're not familiar with Alcon, we are an eye care company. We do a little bit of everything in eye care. We have the pleasurable purpose of dealing with what is, generally speaking, one of the most severe concerns of elderly folks. After memory loss, vision loss is the #1 concern of folks as they age. And we work on refractive error, we work on presbyopia, dry eye, if it's in the eye or if it ...

Alcon (NYSE:ALC) FY Conference January 13, 2026 11:15 AM ET Company ParticipantsDavid Endicott - CEODavid Adlington - Head of the European Medtech and Services ResearchNone - Video NarratorTim Stonesifer - SVP and CFOConference Call ParticipantsNone - AnalystDavid AdlingtonGood morning, everybody. Welcome to day two of the JPMorgan Conference. I'm David Adlington. I head up the European Medtech and Services Research Team in London for JP. It's my pleasure to introduce, we've got David and Tim on stage. Over ...

Summary of Bausch + Lomb FY Conference Call (January 12, 2026) Company Overview - **Company**: Bausch + Lomb (NYSE: BLCO) - **Industry**: Eye health solutions, including consumer products, surgical devices, and pharmaceuticals Key Points and Arguments Company Transformation and Strategy - Bausch + Lomb is undergoing a transformation with a focus on innovation, disciplined execution, and a clear strategy aimed at meeting the growing demand for eye health solutions [1][2] - The company has rebuilt its culture to prioritize accountability, urgency, and a mindset geared towards innovation, leading to a more effective development engine [2][4] Innovation and R&D - The company has seen a significant increase in patent filings, indicating a stronger R&D organization and a shift towards a more innovative culture [3][4] - Innovation is now integrated across all business areas, including product design, digital capabilities, and customer engagement [4] Pipeline and Growth Opportunities - Bausch + Lomb's pipeline is designed for long-term revenue potential, with a focus on consumer, surgical, contact lens, and pharmaceutical segments [5][6] - Upcoming product launches include: - **Blink Triple Care** preservative-free drops (2026) - **PreserVision AREDS 3** for age-related macular degeneration (AMD) (2026) - **Lumify Luxe** for redness relief (2027) [8] - The contact lens segment is expected to grow with the introduction of new daily eye offerings and the innovative **Project Halo**, a bioactive contact lens [9][10] Financial Performance and Projections - The company anticipates a 7% constant currency revenue growth in the consumer segment over the past year, with significant pipeline impacts expected [7] - Expected peak sales from new contact lenses under development could total $1.25 billion, potentially doubling the size of the contact lens business [10] - The pharmaceutical segment, particularly MIEBO and Xiidra, is projected to drive top-line growth and margin improvement [11][12] Surgical Business and Market Position - The surgical business is expected to see growth driven by premium ocular lenses and new product launches, including ELIOS for glaucoma surgery [12][13] - The company aims to improve surgical margins through a shift to higher-margin products and enhanced manufacturing efficiencies [29][30] Financial Metrics and Goals - Bausch + Lomb targets a 23% EBITDA margin by 2028, representing a 600 basis point increase from current levels [38] - The company expects double-digit EPS growth annually, driven by improved operational efficiencies and cost management [42] Market Conditions and Consumer Trends - The contact lens market is projected to grow at a rate of 4% to 6%, with Bausch + Lomb maintaining a strong position despite market slowdowns experienced by competitors [21][22] - The company is optimistic about consumer confidence and pricing power in the market, particularly in the U.S. [22][23] Capital Allocation and Future Plans - Bausch + Lomb plans to focus on strengthening its balance sheet, reducing leverage, and pursuing opportunistic M&A, with no immediate need for large-scale acquisitions [47][48] Additional Important Insights - The company emphasizes a commitment to operational excellence and financial discipline, aiming for significant improvements in cash flow and working capital management [44][45] - Bausch + Lomb's approach to innovation is grounded in addressing real clinical needs, which is expected to create long-term shareholder value [6] This summary encapsulates the key points discussed during the Bausch + Lomb FY Conference Call, highlighting the company's strategic direction, innovation pipeline, financial goals, and market positioning.

STAAR Surgical Company (NASDAQ:STAA) announced Tuesday that it did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. (NYSE:ALC) at the Special Meeting of Stockholders.STAAR intends to terminate its merger agreement with Alcon.No termination fee will be payable by either party, and STAAR will remain a standalone publicly traded company.Stephen Farrell, CEO of STAAR, said, “…In the short term, we will continue to prioritize profitable sales growth while we drive effic ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. O. ...

Core Viewpoint - The company, Liaoning He Eye Hospital Group Co., Ltd., is launching a shareholder reward program to express gratitude to its investors and establish a long-term, diverse shareholder return mechanism [1][5]. Group 1: Activity Content - The program includes personalized eye health service consultants for each participating shareholder, offering "full-process convenient services" [1]. - Discounts on optical products such as orthokeratology lenses, myopia management lenses, and frame glasses will be provided [1]. - Exclusive discounts on diagnostic projects including visual training, genetic testing, and meibomian gland massage therapy are part of the offerings [1]. - Shareholders will receive special discounts on myopia correction refractive surgeries [1]. - Aesthetic medical projects will also be included in the rewards [1]. - Customized eye health check-up plans will be available for shareholders [1]. Group 2: Participation Scope - The program is open to current shareholders, historical shareholders, and future investors, including direct relatives (spouse, parents, children) of the shareholders [2]. Group 3: Activity Locations - The activities will take place at the company's subsidiary hospitals and core city clinics [3]. Group 4: Activity Duration - The program will be executed long-term starting from the date of the announcement [4]. Group 5: Participation Method - More details about the activities will be available through the WeChat account "He Eye Investor Relations," with relevant content to be published on December 26, 2025 [5]. Group 6: Additional Notes - This initiative is a practical measure for the company to implement its shareholder return philosophy and express sincere gratitude for the long-term support and attention from shareholders [5].

Group 1 - Silver Point Capital initiated a new position in Bausch + Lomb Corporation, acquiring approximately 2.6 million shares valued at around $38.7 million as of the end of the quarter [2][6] - The new stake represents 2.8% of Silver Point's reported assets under management (AUM) as of September 30, indicating a significant investment in Bausch + Lomb [3][8] - Bausch + Lomb's stock price was $16.95, reflecting a 13% decline over the past year, contrasting with the S&P 500's 13% increase during the same period [3][4] Group 2 - Bausch + Lomb operates in the eye health sector, offering a range of products including contact lenses, lens care products, ophthalmic pharmaceuticals, and surgical devices across three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical [5] - The company reported a 7% revenue growth to $1.3 billion in the third quarter, with adjusted EBITDA rising to $243 million, while also reaffirming full-year revenue guidance [8] - Despite the revenue growth, Bausch + Lomb experienced a net loss of $28 million compared to a net income of $4 million in the previous year [8]

Core Insights - Bausch + Lomb is positioning itself as a leading company in eye health, emphasizing a commitment to innovation and improvement in standards of care [1][2] - The company has undergone significant operational changes since 2023, focusing on not accepting the status quo and enhancing decision-making processes [2] - The current product pipeline is described as the strongest and most forward-looking in the company's history, grounded in scientific research and a clear purpose [3]

Core Insights - Alcon Inc. (ALC) is recognized as a leader in the eye care industry, benefiting from a strong and diversified market position, which is expected to provide favorable conditions for growth [1] Group 1: Company Overview - Alcon Inc. is positioned as a dominant player in the eye care sector, leveraging its diversified offerings to capitalize on market opportunities [1] Group 2: Market Positioning - The company is experiencing tailwinds that are likely to enhance its competitive advantage and market share in the eye care industry [1] Group 3: Investment Opportunities - The investment group "Value In Corporate Events" focuses on identifying actionable investment opportunities related to significant corporate events such as earnings reports, mergers, and acquisitions, with a particular emphasis on Alcon Inc. [1]

Summary of Bausch + Lomb Investor Day Company Overview - **Company**: Bausch + Lomb (NYSE: BLCO) - **Event**: 2025 Investor Day held on November 13, 2025 Key Industry Insights - **Market Growth**: The eye care market is durable and growing at mid-single digits, with Bausch + Lomb expecting a compound annual growth rate (CAGR) of 5%-7% through 2028 [19][22] - **Consumer Trends**: Increasing consumer interest in self-care, an aging population, and a rise in eye conditions, particularly dry eye, are driving market growth [51] Core Company Strategies - **Financial Excellence**: Emphasis on driving execution, controlling costs, and expanding margins to create sustainable value through 2028 and beyond [16][17] - **Innovation Focus**: A robust pipeline of breakthrough products is expected to deliver significant value beyond 2028, with over 60 active programs in various stages of development [18][34] Financial Targets - **Revenue Growth**: Expected above-market revenue growth with a target of 5%-7% CAGR through 2028 [19][22] - **Margin Expansion**: Targeting an adjusted EBITDA margin of 23% by 2028, reflecting a 600 basis points improvement from 2025 guidance [20][21] - **Cash Flow Generation**: Anticipating cash flow conversion to exceed 50% by 2028, with strong progress already noted in Q3 results [20][28] Product Portfolio Highlights - **Consumer Business**: Strong performance with a 5%-7% CAGR expected, driven by brands like PreserVision, Lumify, and Blink [23][51] - **Pharmaceutical Leadership**: Market leader in dry eye disease with brands Mibo and Xiidra, focusing on innovative treatments [24] - **Surgical Innovations**: Premium IOL portfolio and new product launches are driving growth in the surgical segment [24] Key Product Innovations - **PreserVision AREDS3**: A new formulation targeting all stages of age-related macular degeneration (AMD), expected to launch in 2026 [54][55] - **Lumify Lux**: A new version of the popular redness reliever incorporating hyaluronic acid for enhanced user experience [60][61] - **Blink Triple Care**: An advanced OTC dry eye drop formulation combining hyaluronic acid with nano-emulsion lipids for long-lasting hydration [64] R&D and Innovation - **R&D Transformation**: Significant restructuring to enhance capabilities, focusing on groundbreaking innovations and faster market delivery [33][34] - **Pipeline Potential**: Aiming for peak sales of $7 billion from the current pipeline, with a focus on disruptive innovations rather than incremental improvements [30][31] Market Position and Competitive Advantage - **Leadership in Consumer Eye Health**: Bausch + Lomb is the number one global consumer eye health company, outperforming peers in growth [51][52] - **Brand Trust**: Strong consumer trust in brands like PreserVision, Lumify, and Biotrue, which are highly recommended by eye care professionals [52] Conclusion - Bausch + Lomb is positioned for significant growth through innovative product development, strong financial management, and a commitment to improving eye health standards. The company is confident in its ability to deliver above-market growth and expand profitability through disciplined execution and strategic investments in R&D.